Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
NGHIÊN CỨU LÂM SÀNG Issue: Số 68 (2014) BỆNH MẠCH VÀNH

No translate

Published: October 31, 2014
Views: 468

Abstract

Background: Lp-PLA2 (Lipoprotein-associated phospholipase A2) is an enzyme secreted by macrophages. It is raised in the blood when there is an unstable plaque. Lp-PLA2 is an enzyme combined 80-85% with LDL-c, making plaques brittle in arteries and causing events such as myocardial infarction and stroke. A high blood Lp-PLA2 is a sign that the risk of coronary heart disease and stroke may be higher than normal. Quantification of Lp-PLA2 in blood is used for screening and risk prediction of coronary heart disease. Objectives: To survey the concentration of Lp-PLA2 in patients with acute myocardial infarction; to understand the relationship between blood Lp-PLA2 concentrations and prognostic factors (according to the Killip and TIMI scales) and risk factors such as age, hypertension, BMI, blood glucose, total cholesterol, triglycerides, HDL-c, LDL-c, CK, CK-MB, troponin T, hs-CRP and WBC. Subjects and Methods: We conducted a study on 71 patients: 41 patients diagnosed with myocardial infarction and a control group of 30 without myocardial infarction. Research method: cross-sectional descriptive controlled. Results: 1. The concentration of Lp-PLA2 in patients with acute myocardial infarction was 33.07 ± 26.67 IU/ml, higher than in the control group (14.04 ± 1.1 IU/ml) (p < 0.05). Raised Lp-PLA2 accounted for 73.2% in acute myocardial infarction (p < 0.05). The serum Lp-PLA2 concentration in patients ≥ 60 years of age was 39.38 ± 29.59 IU/ml, higher than in the younger group (22.12 ± 19.14 IU/ml) (p < 0.05). The Lp-PLA2 concentration in men was 36.58 ± 30.79 IU/ml, higher than in women (31.24 ± 24.46 IU/ml). 2. There was a strong positive correlation between Lp-PLA2 concentration and LDL-c (r = 0.5324, p < 0.05). There was a moderate positive correlation between Lp-PLA2 and the TIMI scale (r = 0.3228, p < 0.05), hs-CRP (r = 0.398, p < 0.05), age (r = 0.3044, p < 0.05), hypertension (r = 0.313, p < 0.05), BMI (r = 0.387, p < 0.05), triglycerides (r = 0.3273) and troponin T (r = 0.4109, p < 0.05). There was no correlation between Lp-PLA2 and Killip scale, blood glucose, cholesterol, HDL-c, CK, CK-MB and leukocytes. Hs-CRP, LDL-c and age were predictors of Lp-PLA2 increase, with areas under the ROC curve of 0.818, 0.739 and 0.691 respectively. Conclusion: Plasma Lp-PLA2 was increased in patients with acute myocardial infarction. There was a strong positive correlation between the concentration of Lp-PLA2 and LDL-c, and a moderate positive correlation between Lp-PLA2 and TIMI scale, age, hypertension, hs-CRP, BMI, triglycerides and troponin T. There was no correlation between Lp-PLA2 and Killip scale, blood glucose, cholesterol, HDL-c, CK, CK-MB and leukocytes.

Keywords
Lp-PLA2 acute myocardial infarction hs-CRP LDL-c TIMI score

References

1.
1. Nguyễn Hữu Trâm Em (2010), “Chỉ điểm nguy cơ tim mạch mới: Những nguy cơ lâm sàng”, Hội nghị Tim mạch Miền Trung mở rộng lần thứ 5.
2.
2. Đỗ Văn Hùng (2013), Nghiên cứu nồng độ Lp-PLA2 ở bệnh nhân tăng huyết áp có hội chứng chuyển hóa, tr.48-56.
3.
3. Lê Thị Bích Thuận (2005), Nghiên cứu biến đổi Protein C trong bệnh mạch vành, Luận án Tiến sĩ Y học, Đại học Y Dược Huế, tr.1-117.
4.
4.Ballantyne C.M, Hoogeveen R.C, Bang H et al (2004), “Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and
5.
women in the Atherosclerosis Risk in Communities (ARIC) study”, Circulation, 109, pp.837-842.
6.
5. Brilakis E.S, McConnell J.P, Lennon R.J et al (2004), “Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up”, European heart journal, 26 (2), pp.137 - 144.
7.
6. Corsetti J.P, Rainwater D.L, Moss A.J et al (2006), “High Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Recurrent Coronary Events in Postinfarction Patients”, Clinical chemistry, 52 (7), pp.1331 - 1337.
8.
7. Daniels L.B, Laughlin G.A, Sarno M.J et al (2008), “Lipoprotein-Associated Phospholipase A2 Is anIndependent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population”, The Rancho Bernardo Study, J Am Coll Cardiol, 51, pp.913 - 919.
9.
8. Gerber y, McConnell J.P, Jaffe A.S et al (2006), “Plasma Lipoprotein-associated Phospholipase A2 and prognosis after myocardial infrarction in the community”, Arterioscler thromb vasc boil, 26, pp.2517 - 2522.
10.
9. Gong H, Du y.M, Zhong L et al (2011), “Plasma Lipoprotein-associated Phospholipase A2in Patients with Metabolic Syndrome and Carotid Atherosclerosis”, Lipids in Health and Disease, 10 (13), pp.2- 8.
11.
10. Hatoum i.J, Cook N.R, Nelson J.J et al (2011), “Lipoprotein-Associated Phospholipase A2 Activity Improves Risk Discrimination of Incident Coronary Heart Disease Among women”, Am Heart J, 161 (3), pp.516-522.
12.
11. iribarren C, Gross M.D, Darbinian J.A et al (2005), “Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults. The CARDIA Study”, Arterioscler Thromb Vasc Biol, 25, pp.216 - 221.
13.
12. Killingsworth L.M (2006), PLAC - A Specifi c Marker for Vascular Inflammation.
14.
13. Koenig W and Khuseyinova N (2006), “Emerging Role of Inflammatory Biomarkers in Cardiovascular Risk Assessment”, Department of Internal Medicine II - Cardiology, University of Ulm Medical Center, pp.1-5.
15.
14. Oei H.H.S, Van der Meer i.M, Hofman A et al (2005), “Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study”, Circulation, 111, pp.570-575.
16.
15. Oldgren J, James S.K, Siegbahn A and Wallentin L (2007), “Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients”, European Heart Journal, 28, pp.699-704.
17.
16. Packard C.J, O’Reilly D.S.J, Caslake M.J et al (2000), “Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease. West of Scotland Coronary Prevention Study Group”, N Eng J Med, 343, pp.1148-1155.
18.
University Hospital,pp.1-62.
19.
18. Tsimikas S, Willeit J, Knoflach M et al (2009), “Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome and 10 year cardiovascular and non-cardiovascular mortality: Results from the Bruneck study”, European Heart Journal, 30, pp.107 - 115.
20.
19. Sabatine M.S, Morrow D.A, O’Donoghue M et al (2007), “Prognostic Utility of Lipoprotein- Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease”, Arterioscler Thromb Vasc Biol, 27, pp.2463 - 2469.
21.
20. Zalewski A, Nelson J.J, Hegg L and Macphee C (2006), “Lp-PLA2: A New Kid on the Block”, Clinical Chemistry, 52 (9), pp.1645-1650.

Tác giả

Đoàn Quyết Dũng: Bệnh viện Đa khoa huyện Phú Hoà tỉnh Phú Yên; Lê Văn Tâm: Bệnh viện Trường Đại học Y - Dược Huế; Lê Thị Bích Thuận: Trường Đại học Y Dược Huế;
No translate

Files

Article Views468
Document Views0
Downloads20
Section NGHIÊN CỨU LÂM SÀNG
Category BỆNH MẠCH VÀNH
Pages 241-249
Copyright Holder 2014 Tạp chí Tim mạch học Việt Nam